Abstract: A discharge lamp including an arc envelope defining a chamber and a first opening. A plug is positioned in the first opening through a first seal. The lamp further includes a dosing tube extending away from the chamber, and having a passageway extending into the chamber through a second opening in the arc envelope. The dosing tube is coupled to the arc envelope via a second seal. The first seal, the second seal, or both seals include a braze material having an active metal element in an amount ranging from about 0.1 weight percent to about 10 weight percent, based on the total weight of the braze material.

Abstract: A high intensity discharge lamp includes an electrically insulating arc tube. A sealed shroud encloses the arc tube. An electrically conductive frame member is disposed inside the shroud and is electrically connected to an electrical conductor that extends in the arc tube. Electrically conductive foil is fastened to the frame member and forms a closed loop that encircles a leg of the arc tube by an angle in a range of at least 270 degrees to 360 degrees. The foil can be connected to the frame member and to itself. A distance from an outer surface of a flange of the arc tube leg to a proximal edge of the foil can range from 1.5 to 8 mm. A width of the foil can range from 1 mm to 4 mm.

Abstract: A voidless CMH lamp and a method of making such a lamp are provided. The CMH lamp includes a lamp body that receives at least one end plug. The end plug is constructed from a core of cermet material received within an outer layer of a ceramic material. An electrode is placed into the cermet material. The application of heat causes the cermet material to contract and eliminate voids between the lamp and cermet material. Co-sintering of the lamp, core, and outer layer provides a hermetic seal without necessarily using e.g., a sealing frit. Sintering of the ceramic material surrounding the cermet can be also used to improve light output and photometric performance of the lamp. The creation of one or more openings or recesses in the end plug can also provide performance improvements.

Abstract: A voidless CMH lamp and a method of making such a lamp are provided. The CMH lamp includes a lamp body that receives at least one end plug. The end plug is constructed from a core of cermet material received within an outer layer of a ceramic material. An electrode is placed into the cermet material. The application of heat causes the cermet material to contract and eliminate voids between the lamp and cermet material. Co-sintering of the lamp, core, and outer layer provides a hermetic seal without necessarily using e.g., a sealing frit. Sintering of the ceramic material surrounding the cermet can be also used to improve light output and photometric performance of the lamp. The creation of one or more openings or recesses in the end plug can also provide performance improvements.

Abstract: A lamp includes a discharge vessel with electrodes extending into the discharge vessel and an ionizable fill scaled within the vessel. The fill includes a buffer gas, optionally mercury, and a halide component. The lamp includes available oxygen, sealed within the discharge vessel, at a concentration of at least 0.1 ?mol O/cc.

Abstract: The present disclosure relates to a discharge lamp with improved color point, Dccy and CRI. More specifically, the invention provides a ceramic metal halide (CMH) lamp exhibiting improved color point, Dccy and CRI with little or no loss in other lamp performance parameters. For example, the lamp in accord with at least one embodiment of the invention exhibits excellent lumen output, lamp CCT, and efficacy, in addition to improved color parameters. In one embodiment, the lamp demonstrating these characteristics is a CMH lamp having low levels of indium iodide included in the dose thereof.

Abstract: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors.

Abstract: A high intensity discharge lamp includes an electrically insulating arc tube. A sealed shroud encloses the arc tube. An electrically conductive frame member is disposed inside the shroud and is electrically connected to an electrical conductor that extends in the arc tube. Electrically conductive foil is fastened to the frame member and forms a closed loop that encircles a leg of the arc tube by an angle in a range of at least 270 degrees to 360 degrees. The foil can be connected to the frame member and to itself. A distance from an outer surface of a flange of the arc tube leg to a proximal edge of the foil can range from 1.5 to 8 mm. A width of the foil can range from 1 mm to 4 mm.

Abstract: A lamp includes a discharge vessel with electrodes extending into the discharge vessel and an ionizable fill sealed within the vessel. The fill includes a buffer gas, optionally mercury, and a halide component comprising a sodium halide, a lanthanum halide, a thallium halide, and a calcium halide. The lanthanum halide is present in the halide component at a mol fraction of at least 0.03.

Abstract: The invention relates generally to ceramic metal halide lamps. More particularly, the invention relates to low wattage ceramic metal halide lamps having enhanced color control. In one embodiment according to the invention, such lamps may be characterized by a shank length (SL) to shank diameter (SD) ratio of between 5.1 and 15.5. Further, the lamp exhibits a sigma CCT of less than about 100° K.

Abstract: The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors.

Abstract: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors.

Abstract: An electroded high watt ceramic metal halide lamp assembly is provided which comprises a light transmissive arc-tube surrounding at least one electrode, a fill disposed in the arc-tube that includes at least one metal halide component and at least one metallic halide getter. The metallic halide getter has a Gibbs Free Energy greater than mercury halide and less than thallium halide, vapor pressure less than mercury halide, free energy of formation of oxide less than Aluminum oxide.

Abstract: A lamp includes a discharge vessel with electrodes extending into the discharge vessel and an ionizable fill sealed within the vessel. The fill includes a buffer gas, optionally mercury, and a halide component comprising a sodium halide, a lanthanum halide, a thallium halide, and a calcium halide. The lanthanum halide is present in the halide component at a mol fraction of at least 0.03.

Abstract: A lamp includes a discharge vessel with electrodes extending into the discharge vessel and an ionizable fill scaled within the vessel. The fill includes a buffer gas, optionally mercury, and a halide component. The lamp includes available oxygen, sealed within the discharge vessel, at a concentration of at least 0.1 ?mol O/cc.

Abstract: An electroded high watt ceramic metal halide lamp assembly is provided which comprises a light transmissive arc-tube surrounding at least one electrode, a fill disposed in the arc-tube that includes at least one metal halide component and at least one metallic halide getter. The metallic halide getter has a Gibbs Free Energy greater than mercury halide and less than thallium halide, vapor pressure less than mercury halide, free energy of formation of oxide less than Aluminum oxide.

Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

Abstract: A lamp includes a discharge vessel with electrodes extending into the discharge vessel and an ionizable fill sealed within the vessel. The fill includes a buffer gas, optionally mercury, and a halide component comprising a sodium halide, a lanthanum halide, a thallium halide, and a calcium halide.

Abstract: Discharge tubes for a lamp include a body portion with a first end, a second end, and a tubular member defining an interior area. The tubular member extends along an elongated axis between the first end and the second end. The discharge tube further includes a first end portion provided at the first end of the body portion. The first end portion includes a first tubular extension having a first through passage in communication with the interior area. The first end portion further includes a first transition section connected between the first tubular extension and the body portion.

Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.